The CTD² Network and Cancer Systems Biology Consortium organized a virtual symposium series titled “Multidisciplinary Approaches to Understand Cancer Treatment Resistance”. Please join us on 11/16, 11/17, 12/2, 12/16, and 12/17. Click here to view the registration website.
Publications
644 Publications Available
Cancer Discovery
Clinical Cancer Research
CTD2 UCSF-2 review on the importance of 4EBP1 as a biomarker for the efficacy of PI3K-AKT-mTOR inhibitors in glioblastoma.
Molecular Cancer Research
Researchers identified that MAPK-interacting kinase 1 (MNK1) is overexpressed in the mesenchymal (MES) phenotype of glioblastoma, which may cause therapeutic resistance to arsenic trioxide (ATO). This study supports the use of the MNK inhibitor along with ATO to treat MES glioblastoma patients.
Nature Communications
Scientific Reports
Nature Genetics
CTD2 researchers at DFCI developed CERES, a computational approach to improve the specificity of genome-wide loss-of-function CRISPR-Cas9 screens by decreasing the discovery of false-positives.
Nature Methods
Bioinformatics
CTD2 scientists at Emory University developed the OncoPPi Portal, an interactive web resource to explore cancer-relevant protein-protein interactions that were experimentally identified in cancer cell lines.
Cell Systems
CTD2 scientists used Project Achilles (RNAi screening) data in a community DREAM challenge (that assessed computational models focused on biomedical research problems) to predict the gene essentiality. This study provides insights into factors influencing the ability to predict gene essentiality.